IL151646A0 - Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction - Google Patents

Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction

Info

Publication number
IL151646A0
IL151646A0 IL15164601A IL15164601A IL151646A0 IL 151646 A0 IL151646 A0 IL 151646A0 IL 15164601 A IL15164601 A IL 15164601A IL 15164601 A IL15164601 A IL 15164601A IL 151646 A0 IL151646 A0 IL 151646A0
Authority
IL
Israel
Prior art keywords
phosphodicesterase
pyrazinones
pyrido
inhibitors
erectile dysfunction
Prior art date
Application number
IL15164601A
Other languages
English (en)
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of IL151646A0 publication Critical patent/IL151646A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15164601A 2000-03-14 2001-03-06 Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction IL151646A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10012373A DE10012373A1 (de) 2000-03-14 2000-03-14 Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
PCT/EP2001/002485 WO2001068097A1 (de) 2000-03-14 2001-03-06 VERWENDUNG VON PYRIDO[3,2-e]-PYRAZINONEN ALS INHIBITOREN DER PHOSPHODIESTERASE 5 ZUR THERAPIE VON EREKTILER DYSFUNKTION

Publications (1)

Publication Number Publication Date
IL151646A0 true IL151646A0 (en) 2003-04-10

Family

ID=7634668

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15164601A IL151646A0 (en) 2000-03-14 2001-03-06 Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction

Country Status (14)

Country Link
EP (1) EP1267877A1 (xx)
JP (1) JP2003528056A (xx)
AR (1) AR028250A1 (xx)
AU (1) AU2001244192A1 (xx)
BG (1) BG107077A (xx)
BR (1) BR0109163A (xx)
CZ (1) CZ20023078A3 (xx)
DE (1) DE10012373A1 (xx)
HU (1) HUP0300551A2 (xx)
IL (1) IL151646A0 (xx)
NO (1) NO20024364L (xx)
RU (1) RU2002127413A (xx)
SK (1) SK13232002A3 (xx)
WO (1) WO2001068097A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
AU2008329775A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
BR112014031730B1 (pt) * 2012-06-18 2023-05-16 Dart Neuroscience (Cayman) Ltd Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
JP6420400B2 (ja) * 2017-04-12 2018-11-07 ダート・ニューロサイエンス・(ケイマン)・リミテッド 置換ピリジンアゾロピリミジン−5−(6h)−オン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
WO1993020077A1 (en) * 1992-04-03 1993-10-14 Yamanouchi Pharmaceutical Co., Ltd. Fused quinoxalinone derivative and pharmaceutical composition containing the same
DE4228095A1 (de) * 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
DE4338948A1 (de) * 1993-11-15 1995-05-18 Carlen Judith Verwendung von PDE-Inhibitoren bei der Behandlung erektiler Dysfunktionen
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
DE19728301A1 (de) * 1997-07-03 1999-01-07 Dresden Arzneimittel Verwendung von Inhibitoren der Phosphodiesterase 4 für die Behandlung der allergischen Rhinitis

Also Published As

Publication number Publication date
AU2001244192A1 (en) 2001-09-24
BG107077A (bg) 2003-05-30
SK13232002A3 (sk) 2003-05-02
CZ20023078A3 (cs) 2003-03-12
AR028250A1 (es) 2003-04-30
HUP0300551A2 (hu) 2003-07-28
BR0109163A (pt) 2002-11-26
NO20024364D0 (no) 2002-09-12
EP1267877A1 (de) 2003-01-02
JP2003528056A (ja) 2003-09-24
NO20024364L (no) 2002-09-27
WO2001068097A1 (de) 2001-09-20
DE10012373A1 (de) 2001-09-20
RU2002127413A (ru) 2004-02-27

Similar Documents

Publication Publication Date Title
IL151646A0 (en) Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction
IL138907A0 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
HK1051368A1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
EP1027054A4 (en) LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
HUP0200912A3 (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
HUP0300477A3 (en) Daily treatment for erectile dysfunction using a composition containing pde5 inhibitors
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
EP1677754A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE EFFECTIVE DYSFUNCTION
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
EP1161255A4 (en) METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
IL154642A0 (en) Treatment of urinary dysfunction
WO2002041894A3 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
AU2002246924A8 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
PL362980A1 (en) Treatment of sexual dysfunction
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
AU2000275972A1 (en) Pde iii inhibitors for treating sexual dysfunction
AU2001237379A1 (en) Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction
ZA200203069B (en) Peptides for treatment of erectile dysfunction.
EP1395593A4 (en) NEW PYRAZOLOPYRIMIDINTHION DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS A THERAPEUTIC IN ERECTILER DYSFUNCTION
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
ZA992793B (en) Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction.
AU2002219247A1 (en) Use of levosimendan for treating erictile dysfunction

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)

Owner name: ELBION GMBH

Free format text: FORMER NAME:ELBION AG